Bildkälla: Stockfoto

Cyxone: A Shot at the Big Leagues - Redeye

Redeye initiates coverage of Cyxone, a Swedish biotech developing disease-modifying drugs for Rheumatoid Arthritis (RA) and Multiple Sclerosis (MS), as well as a treatment for Covid-19. An experienced management team, a de-risked lead candidate and undemanding valuation underpin our interest in the case.

The stock’s undemanding current levels provide an attractive entry point. The stock is trading at low levels, we believe, due on-going warrant program, Covid-related uncertainty and negative sentiment in the biotech sector as a whole. Upside to the Base Case value of SEK 7,5 Per Share derived from Redeye’s fundamental analysis is roughly 60%.
Börsvärldens nyhetsbrev
ANNONSER